RhumbLine Advisers
CSTL icon

RhumbLine Advisers’s Castle Biosciences CSTL Stock Holding History

RhumbLine Advisers’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$942K Sell
38,378
-90
-0.2% -$2.95K ﹤0.01% 2222
2025
Q4 		$1.5M Sell
38,468
-5,290
-12% -$171K ﹤0.01% 2030
2025
Q3 		$996K Sell
43,758
-1,639
-4% -$33.3K ﹤0.01% 2241
2025
Q2 		$927K Buy
45,397
+6,211
+16% +$115K ﹤0.01% 2287
2025
Q1 		$784K Sell
39,186
-706
-2% -$17.5K ﹤0.01% 2289
2024
Q4 		$1.06M Sell
39,892
-1,009
-2% -$30.7K ﹤0.01% 2224
2024
Q3 		$1.17M Sell
40,901
-995
-2% -$25.3K ﹤0.01% 2187
2024
Q2 		$912K Buy
41,896
+2,988
+8% +$66.6K ﹤0.01% 2302
2024
Q1 		$862K Buy
38,908
+1,000
+3% +$21.8K ﹤0.01% 2330
2023
Q4 		$818K Buy
37,908
+60
+0.2% +$1.06K ﹤0.01% 2376
2023
Q3 		$639K Buy
37,848
+539
+1% +$9.43K ﹤0.01% 2460
2023
Q2 		$512K Sell
37,309
-1,986
-5% -$40.2K ﹤0.01% 2671
2023
Q1 		$893K Buy
39,295
+1,383
+4% +$33.8K ﹤0.01% 2174
2022
Q4 		$892K Buy
37,912
+393
+1% +$9.11K ﹤0.01% 2194
2022
Q3 		$978K Buy
37,519
+3,239
+9% +$90.8K ﹤0.01% 2141
2022
Q2 		$752K Buy
34,280
+12,344
+56% +$287K ﹤0.01% 2281
2022
Q1 		$984K Buy
21,936
+1,038
+5% +$42.9K ﹤0.01% 2138
2021
Q4 		$896K Sell
20,898
-357
-2% -$18.7K ﹤0.01% 2254
2021
Q3 		$1.41M Buy
21,255
+832
+4% +$58.5K ﹤0.01% 2072
2021
Q2 		$1.5M Buy
20,423
+5,913
+41% +$391K ﹤0.01% 2079
2021
Q1 		$993K Buy
14,510
+1,007
+7% +$75.7K ﹤0.01% 2191
2020
Q4 		$907K Buy
13,503
+1,027
+8% +$55.7K ﹤0.01% 2178
2020
Q3 		$642K Sell
12,476
-288
-2% -$12.8K ﹤0.01% 2173
2020
Q2 		$481K Buy
12,764
+3,520
+38% +$120K ﹤0.01% 2361
2020
Q1 		$276K Buy
+9,244
New +$279K ﹤0.01% 2446

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RhumbLine Advisers's CSTL Position: Q1 2026 in Review

RhumbLine Advisers reduced its Castle Biosciences (CSTL) stake by 0.23% in Q1 2026, selling an estimated $2.95K and leaving 38,378 shares worth $942K. The position accounts for ﹤0.01% of the portfolio, ranked #2222.

RhumbLine Advisers first reported a position in CSTL in Q1 2020 and has held it in 25 quarters since. The position peaked at $1.5M in Q2 2021. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • RhumbLine Advisers held 38,378 shares of Castle Biosciences worth $942K as of Q1 2026.
  • RhumbLine Advisers sold 90 Castle Biosciences shares in Q1 2026, an estimated $2.95K.
  • Castle Biosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2222 holding.
  • RhumbLine Advisers first reported a position in Castle Biosciences in Q1 2020 and has held it in 25 quarters since.
  • RhumbLine Advisers's Castle Biosciences position peaked at $1.5M in Q2 2021.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.